Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Second-line therapy in non-small-cell lung cancer: the DELTA between different genotypes widens.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology - 20 Jun 2014

Zer Alona, Leighl Natasha B

Abstract excerpt

No abstract is available from the source.

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Docetaxel
Share to Erlotinib Hydrochloride
Share to Glutamates
Share to Palliative Care

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Pemetrexed

Share to Pleural Effusion, Malignant

Share to Radiotherapy, Adjuvant

Share to Taxoids

Source

Identifiers

PMID: 24841982
DOI: 10.1200/JCO.2013.54.4270

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Second-line therapy in non-small-cell lung cancer: the DELTA between different genotypes widens.PMID 24841982Read ↗

Changing the Therapeutic Landscape in Non-small Cell Lung Cancers: the Evolution of Comprehensive Molecular Profiling Improves Access to TherapySemantic proximity Read ↗

Second-Line Chemotherapy and Beyond for Non-Small Cell Lung Cancer.Semantic proximity Read ↗

Molecular Analysis-Based Treatment Strategies for the Management of Non-small Cell Lung CancerSemantic proximity Read ↗

Optimal Therapy for Advanced Non-Small Cell Lung Cancer Without Driver Alterations.Semantic proximity Read ↗

Exploring the future of non-small cell lung cancer treatment.Semantic proximity Read ↗

Personalized therapy for non-small cell lung cancer: hype or clinical reality?Semantic proximity Read ↗

Drug resistance in non-small cell lung Cancer (NSCLC): Impact of genetic and non-genetic alterations on therapeutic regimen and responsivenessSemantic proximity Read ↗

WITHDRAWN: GFH375 in Patients with Previously Treated Non-Small Cell Lung Cancer and KRASG12D Mutations: A First-in-Human StudySemantic proximity Read ↗

Pharmacogenetics of conventional chemotherapy in non-small-cell lung cancer: a changing landscape?Semantic proximity Read ↗

BRAF Adds an Additional Piece of the Puzzle to Precision Oncology-Based Treatment Strategies in Lung Cancer.Semantic proximity Read ↗

Treatment choice in EGFR-mutant non-small-cell lung cancer.Semantic proximity Read ↗

Lung cancer: not just for smokers. People who never smoked may have a different form of the disease that responds better to a new generation of targeted medications.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.